RADNOR, PA., 2024 年 10 月 16 日 — Certara, Inc. （纳斯达克股票代码：CERT), a global leader in model-informed drug development, today announced the appointment of John Reynders, PhD to its Board of Directors, effective 2024 年 10 月 15 日.   

“We are excited to welcome an accomplished pharmaceutical industry leader with a track record of success to Certara’s Board,” said William F. Feehery, PhD, CEO of Certara. “John’s expertise in artificial intelligence, data science, and life science will provide immense value. We will draw on that expertise as we continue to develop and integrate transformational software and services that accelerate new medicines and increase the productivity of pharma R&D.” 

Dr. Reynders has over 25 years of experience in the pharmaceutical and tech industries.  He was the founding CIO of Moderna where he led the data-sciences capabilities to design mRNA therapies. Most recently, he was Chief Data Sciences Officer at Neumora, a biotech focused on brain diseases. Before that, he held various executive positions leading data-sciences, informatics, and technology organizations at Alexion Pharmaceuticals, AstraZeneca, Johnson & Johnson, Eli Lilly, and Celera. 

“I am pleased to join Certara’s Board of Directors and help build on their unique biosimulation portfolio, scientific expertise, and data assets. They are at the intersection of data and life sciences which is where I’ve spent most of my career,” said Dr. Reynders. “I look forward to working with the other board members and Certara’s leadership team to advance the Company’s next phase of growth.” 

关于 Certara  

Certara 致力于通过生物模拟软件、技术和服务加速药物研发，改变传统的药物研发方式。其客户包括超 2,400 家生物制药公司、学术机构和来自 66 个国家的监管机构。Learn more at www.certara.com.  

Certara Contact:  
Sheila Rocchio  
{1}   

Media Contact:  
Alyssa Horowitz  
{1}